In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype AssignmentM. Aragri, Giustino Parruti, Velia Chiara Di Maio et al.|Journal of Hepatology|2016Cited by 1
The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for cautionValeria Cento, Francesca Ceccherini‐Silberstein, Ye. A. Troshina et al.|Journal of Hepatology|2017Cited by 1
Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitorsValeria Cento, Francesca Ceccherini‐Silberstein, F.P. Antonucci et al.|Digestive and Liver Disease|2014Cited by 0
P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORSValeria Cento, Francesca Ceccherini‐Silberstein, Velia Chiara Di Maio et al.|Journal of Hepatology|2014Cited by 0
Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohortLoreta A. Kondili, Vincenza Calvaruso, Mg Quaranta et al.|Journal of Hepatology|2018Cited by 0